Etigilimab (MPH313)
For patients with advanced or metastatic solid tumors
Our pipeline
At Mereo, we unlock the potential of rare disease and tumor therapies that were not being progressed in pharmaceutical or biotechnology companies – creating new possibilities for all our stakeholders, from our investors to the patients that need us most.
Our pipeline currently consists of six clinical-stage product candidates.
Core programs
We have already delivered three successful Phase 2 studies with a Phase 2 and Phase 1b/2 ongoing.
Core programs
Partnered and Partnering Opportunities on Non-Core Programs
We have two additional programs with current partnering opportunities. Navicixizumab has been licensed out to OncXerna.
Navicixizumab (OMP305B83)
For the treatment of platinum-resistant ovarian cancer. Navicixizumab has been partnered with OncXerna Therapeutics Inc. for further development.
Acumapimod (BCT197)
For the treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”).
Leflutrozole (BGS649)
For the treatment of male infertility associated with hypogonadotropic hypogonadism (“HH”).
Partnered and partnering opportunities on non-core programs
Pipeline News
Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency- associated Emphysema
09 May 2022Mereo BioPharma announces positive topline results from ASTRAEUS a Phase 2 trial of alvelestat in Alpha-1 Antitrypsin Deficiency- associated Emphysema.
Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat
06 May 2022Mereo BioPharma Group plc today announced it will host a conference call on Monday, May 9, 2022 at 10:30 a.m. ET to review top-line clinical data from its “ASTRAEUS” Phase 2 Study of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema.
Navicixizumab Phase 1b Data Has Been Published in the Journal of Clinical Oncology
22 April 2022Mereo BioPharma's partner for the development of Navicixizumab, OncXerna Therapeutics Inc. announced that Navicixizumab Phase 1b data has been published in the Journal of Clinical Oncology.
Our Partner Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta
20 April 2022Mereo BioPharma's partner for the development of setrusumab, Ultragenyx Pharmaceutical Inc. today announced the first patient has been dosed in a clinical study for the treatment of Osteogenesis Imperfecta (OI) in patients ages 5 to <26 years of age